Deciphering the functional dynamics of the immune system during (immune)therapy in children with neuroblastoma
Recruiting
- Conditions
- Neuroblastoma10027656
- Registration Number
- NL-OMON52494
- Lead Sponsor
- Prinses Máxima Centrum voor Kinderoncologie
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 70
Inclusion Criteria
Neuroblastoma, between 1 and 18 years at diagnosis
Neuroblastoma histological proven diagnosis
Informed consent
Initial staging of the tumor
Exclusion Criteria
Incomplete informed consent
Pregnancy
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Main study parameters/endpoints: immune profiles from NBL patients during<br /><br>(immune)therapy, different percentages (and absolute numbers) anx fuction of<br /><br>immune cells between patients and treatment cycles, functionality in particular<br /><br>NK, T effector and Treg cells, and anti-GD2 plasma levels </p><br>
- Secondary Outcome Measures
Name Time Method <p>anti-GD2 quantification/measurements</p><br>